The National Institutes of Health, America's premier biomedical research agency, has approved far fewer new grants in the second year of the Trump administration than it did in comparable periods over the past decade, according to researchers and agency insiders familiar with the funding process.

The slowdown represents a significant shift for an agency that distributes roughly $48 billion annually to scientists at universities, hospitals, and research institutions across the country. These grants fund everything from basic cancer biology to clinical trials for new treatments, forming the backbone of American medical research.

Multiple factors appear to be converging to create bottlenecks in the grant review process. According to interviews with current and former NIH personnel, as reported by the New York Times, the agency has renewed efforts to screen grant applications for terms or research areas that may be politically sensitive. Simultaneously, the NIH has experienced notable personnel losses in key administrative and scientific positions responsible for managing the grant review workflow.

The Scale of the Slowdown

While precise figures vary by institute within the NIH's 27 centers, researchers report delays of several months beyond typical timelines for hearing back about grant applications. Some investigators say they've received requests to revise or clarify language in proposals that would have sailed through review processes in previous years.

The practical impact extends beyond individual scientists. Research teams often cannot hire postdoctoral fellows or graduate students without confirmed funding. Laboratory equipment purchases are delayed. Clinical trials struggle to launch on schedule.

For early-career researchers, the timing is particularly consequential. Many scientists apply for their first independent grants in their early-to-mid thirties. Delays of six months to a year can mean the difference between establishing a research program and abandoning academic science for industry positions.

Political Screening and Research Independence

The reported screening for "disfavored terms" raises fundamental questions about scientific independence. Historically, the NIH has operated under a peer review system designed to insulate funding decisions from political considerations. Scientists with expertise in a given field evaluate proposals based on scientific merit, feasibility, and potential impact.

Any systematic screening for particular words or topics represents a departure from this model. While the specific terms being flagged have not been publicly disclosed, researchers in fields including climate health impacts, reproductive biology, and health disparities report particular scrutiny.

The tension between political oversight and scientific autonomy is not new. Every administration grapples with how to balance accountability for public funds with the need for researchers to follow evidence wherever it leads. However, the current reports suggest a more direct intervention in the grant pipeline than has been typical in recent decades.

Personnel Losses Compound Delays

Equally concerning to many in the research community is the loss of experienced personnel who manage the complex grant review process. The NIH employs thousands of program officers, scientific review officers, and administrative staff who coordinate peer review, communicate with applicants, and shepherd proposals through multiple stages of evaluation.

These positions require specialized knowledge of both scientific fields and federal grant regulations. When experienced staff leave, their institutional knowledge leaves with them. Training replacements takes months, during which application processing slows.

The personnel challenges come at a time when the NIH was already struggling with an aging workforce and competition from higher-paying private sector positions. The biotech industry has been particularly aggressive in recruiting talent with NIH experience, offering salaries that federal pay scales cannot match.

Ripple Effects Through Research Institutions

Universities and medical centers structure their research operations around predictable NIH funding cycles. When those cycles become unpredictable, the effects cascade through institutional budgets and planning.

Many institutions use internal bridge funding to keep research teams intact during short gaps between grants. However, these emergency funds are limited and cannot sustain prolonged uncertainty. Some universities have begun warning faculty that they may need to reduce laboratory space or staff if funding delays continue.

The situation also affects the next generation of scientists. Graduate students and postdoctoral fellows depend on grant-funded positions. When those positions disappear or remain unfilled due to funding uncertainty, talented young researchers may choose other careers entirely.

Historical Context and Comparisons

NIH funding has weathered political transitions before. The agency saw budget fluctuations during previous administrations, and researchers have long complained about success rates for grant applications that typically hover around 20 percent for some programs.

However, the current situation appears distinct in combining reduced approval rates with procedural changes to how applications are evaluated. Previous slowdowns were generally tied to budget constraints or government shutdowns—temporary disruptions to an otherwise consistent process.

The concern among many in the scientific community is that the current changes may represent a more fundamental shift in how the NIH operates, with potential long-term implications for American biomedical research competitiveness.

What This Means for Public Health

The practical implications extend beyond academic careers and institutional budgets. NIH-funded research has produced transformative medical advances, from cancer immunotherapies to antiviral treatments. The mRNA vaccine technology that proved crucial during the COVID-19 pandemic emerged from decades of NIH-supported basic research.

Slowing the pace of new research means slowing the pipeline of future medical breakthroughs. While ongoing studies continue, the absence of new projects starting today means fewer potential treatments emerging five or ten years from now.

Research on rare diseases is particularly vulnerable. These conditions often lack commercial appeal for pharmaceutical companies, making NIH funding essential for any progress. Delays in rare disease research can leave small patient communities without hope of new treatments for years.

The NIH has not released an official statement addressing the reported slowdown in grant approvals or the factors contributing to it. The agency continues to process applications and fund research across its institutes, though at what appears to be a reduced pace compared to recent years.

For now, researchers across the country are adjusting to a new reality of longer waits, more uncertainty, and more careful consideration of how they describe their work. The full impact of these changes on American biomedical research may not be clear for years to come.